Anti-Tuberculosis Therapeutics Market by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2023-2028
The global anti-tuberculosis therapeutics market size reached US$ 1,354.79 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,991.34 Million by 2028, exhibiting a growth rate (CAGR) of 6.70% during 2023-2028. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.
Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. In recent years, anti-tuberculosis therapeutics have gained traction as it also involves supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise.
Anti-Tuberculosis Therapeutics Market Trends:
One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the market growth. Other than this, the development of new drugs and treatment strategies is also driving the anti-tuberculosis therapeutics market. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of TB. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of TB, leading to timely initiation of treatment and better patient outcomes, which represents another major growth-inducing factor. Furthermore, the increase in healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment has also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global anti-tuberculosis therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on the disease type, diagnosis and treatment, and end user.
Disease Type Insights:
Active TB
Latent TB
Others
The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the disease type. This includes active TB, latent TB, and others.
Diagnosis and Treatment Insights:
Diagnosis
Blood Tests
Imaging Tests
Sputum Tests
Others
Treatment
First-Line of Drugs
Isoniazid
Ethambutol
Rifampin
Others
Second-Line of Drugs
Thiacetazone
Paraaminosalicyclic Acid (PAS)
Others
Others
A detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood tests, imaging tests, sputum tests, and others), treatment (first-line of drugs (isoniazid, ethambutol, rifampin, and others) second-line of drugs (thiacetazone, paraaminosalicyclic acid (PAS), and others), and others
End User Insights:
Hospitals
Specialty Clinics
Homecare
Others
The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the end user. This includes hospitals, specialty clinics, homecare, and others.
Regional Insights:
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global anti-tuberculosis therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include F Hoffmann-La Roche Ltd., Lannett Company Inc., Lupin Limited, Macleods Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market?
What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market?
What are the key regional markets?
Which countries represent the most attractive anti-tuberculosis therapeutics market?
What is the breakup of the market based on the disease type?
Which is the most attractive disease type in the anti-tuberculosis therapeutics market?
What is the breakup of the market based on the diagnosis and treatment?
Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market?
What is the breakup of the market based on end user?
Which is the most attractive end user in the anti-tuberculosis therapeutics market?
What is the competitive structure of the global anti-tuberculosis therapeutics market?
Who are the key players/companies in the global anti-tuberculosis therapeutics market?
Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. In recent years, anti-tuberculosis therapeutics have gained traction as it also involves supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise.
Anti-Tuberculosis Therapeutics Market Trends:
One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the market growth. Other than this, the development of new drugs and treatment strategies is also driving the anti-tuberculosis therapeutics market. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of TB. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of TB, leading to timely initiation of treatment and better patient outcomes, which represents another major growth-inducing factor. Furthermore, the increase in healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment has also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global anti-tuberculosis therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on the disease type, diagnosis and treatment, and end user.
Disease Type Insights:
Active TB
Latent TB
Others
The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the disease type. This includes active TB, latent TB, and others.
Diagnosis and Treatment Insights:
Diagnosis
Blood Tests
Imaging Tests
Sputum Tests
Others
Treatment
First-Line of Drugs
Isoniazid
Ethambutol
Rifampin
Others
Second-Line of Drugs
Thiacetazone
Paraaminosalicyclic Acid (PAS)
Others
Others
A detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood tests, imaging tests, sputum tests, and others), treatment (first-line of drugs (isoniazid, ethambutol, rifampin, and others) second-line of drugs (thiacetazone, paraaminosalicyclic acid (PAS), and others), and others
End User Insights:
Hospitals
Specialty Clinics
Homecare
Others
The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the end user. This includes hospitals, specialty clinics, homecare, and others.
Regional Insights:
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global anti-tuberculosis therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include F Hoffmann-La Roche Ltd., Lannett Company Inc., Lupin Limited, Macleods Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market?
What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market?
What are the key regional markets?
Which countries represent the most attractive anti-tuberculosis therapeutics market?
What is the breakup of the market based on the disease type?
Which is the most attractive disease type in the anti-tuberculosis therapeutics market?
What is the breakup of the market based on the diagnosis and treatment?
Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market?
What is the breakup of the market based on end user?
Which is the most attractive end user in the anti-tuberculosis therapeutics market?
What is the competitive structure of the global anti-tuberculosis therapeutics market?
Who are the key players/companies in the global anti-tuberculosis therapeutics market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL ANTI-TUBERCULOSIS THERAPEUTICS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY DISEASE TYPE
6.1 Active TB
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Latent TB
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast
7 MARKET BREAKUP BY DIAGNOSIS AND TREATMENT
7.1 Diagnosis
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Blood Tests
7.1.2.2 Imaging Tests
7.1.2.3 Sputum Tests
7.1.2.4 Others
7.1.3 Market Forecast
7.2 Treatment
7.2.1 Market Trends
7.2.2 Key Segments
7.2.2.1 First-Line of Drugs
7.2.2.1.1 Major Types
7.2.2.1.1.1 Isoniazid
7.2.2.1.1.2 Ethambutol
7.2.2.1.1.3 Rifampin
7.2.2.1.1.4 Others
7.2.2.2 Second-Line of Drugs
7.2.2.2.1 Major Types
7.2.2.2.1.1 Thiacetazone
7.2.2.2.1.2 Paraaminosalicyclic Acid (PAS)
7.2.2.2.1.3 Others
7.2.2.3 Others
7.2.2 Market Forecast
8 MARKET BREAKUP BY END USER
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Specialty Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Homecare
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 DRIVERS, RESTRAINTS, AND OPPORTUNITIES
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 F. Hoffmann-La Roche Ltd.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 SWOT Analysis
14.3.2 Lannett Company Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Lupin Limited
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Macleods Pharmaceuticals Limited
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Otsuka Pharmaceutical Co. Ltd
14.3.5.1 Company Overview
14.3.5.2 Product PortfolioKindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL ANTI-TUBERCULOSIS THERAPEUTICS MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY DISEASE TYPE
6.1 Active TB
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Latent TB
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast
7 MARKET BREAKUP BY DIAGNOSIS AND TREATMENT
7.1 Diagnosis
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Blood Tests
7.1.2.2 Imaging Tests
7.1.2.3 Sputum Tests
7.1.2.4 Others
7.1.3 Market Forecast
7.2 Treatment
7.2.1 Market Trends
7.2.2 Key Segments
7.2.2.1 First-Line of Drugs
7.2.2.1.1 Major Types
7.2.2.1.1.1 Isoniazid
7.2.2.1.1.2 Ethambutol
7.2.2.1.1.3 Rifampin
7.2.2.1.1.4 Others
7.2.2.2 Second-Line of Drugs
7.2.2.2.1 Major Types
7.2.2.2.1.1 Thiacetazone
7.2.2.2.1.2 Paraaminosalicyclic Acid (PAS)
7.2.2.2.1.3 Others
7.2.2.3 Others
7.2.2 Market Forecast
8 MARKET BREAKUP BY END USER
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Specialty Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Homecare
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 DRIVERS, RESTRAINTS, AND OPPORTUNITIES
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 F. Hoffmann-La Roche Ltd.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 SWOT Analysis
14.3.2 Lannett Company Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Lupin Limited
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Macleods Pharmaceuticals Limited
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Otsuka Pharmaceutical Co. Ltd
14.3.5.1 Company Overview
14.3.5.2 Product PortfolioKindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
LIST OF TABLES
Table 1: Global: Anti-Tuberculosis Therapeutics Market: Key Industry Highlights, 2022 & 2028
Table 2: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
Table 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Diagnosis and Treatment (in Million US$), 2023-2028
Table 4: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by End User (in Million US$), 2023-2028
Table 5: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Anti-Tuberculosis Therapeutics Market: Competitive Structure
Table 7: Global: Anti-Tuberculosis Therapeutics Market: Key Players
Table 1: Global: Anti-Tuberculosis Therapeutics Market: Key Industry Highlights, 2022 & 2028
Table 2: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
Table 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Diagnosis and Treatment (in Million US$), 2023-2028
Table 4: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by End User (in Million US$), 2023-2028
Table 5: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Anti-Tuberculosis Therapeutics Market: Competitive Structure
Table 7: Global: Anti-Tuberculosis Therapeutics Market: Key Players
LIST OF FIGURES
Figure 1: Global: Anti-Tuberculosis Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017-2022
Figure 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 4: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Disease Type (in %), 2022
Figure 5: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Diagnosis and Treatment (in %), 2022
Figure 6: Global: Anti-Tuberculosis Therapeutics Market: Breakup by End User (in %), 2022
Figure 7: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Region (in %), 2022
Figure 8: Global: Anti-Tuberculosis Therapeutics (Active TB) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Anti-Tuberculosis Therapeutics (Active TB) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Anti-Tuberculosis Therapeutics (Treatment) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Anti-Tuberculosis Therapeutics (Treatment) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Anti-Tuberculosis Therapeutics (Homecare) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Anti-Tuberculosis Therapeutics (Homecare) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: North America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: North America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: United States: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: United States: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: Canada: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: Canada: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: Asia-Pacific: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: Asia-Pacific: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: China: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: China: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: Japan: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: Japan: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: India: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: India: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: South Korea: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: South Korea: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: Australia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: Australia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: Indonesia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: Indonesia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Europe: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Europe: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: Germany: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: Germany: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: France: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: France: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: United Kingdom: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: United Kingdom: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: Italy: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: Italy: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: Spain: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: Spain: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Russia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Russia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Latin America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Latin America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Brazil: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Brazil: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Mexico: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Mexico: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 72: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 73: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Breakup by Country (in %), 2022
Figure 74: Middle East and Africa: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 75: Global: Anti-Tuberculosis Therapeutics Industry: Drivers, Restraints, and Opportunities
Figure 76: Global: Anti-Tuberculosis Therapeutics Industry: Value Chain Analysis
Figure 77: Global: Anti-Tuberculosis Therapeutics Industry: Porter's Five Forces Analysis
Figure 1: Global: Anti-Tuberculosis Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017-2022
Figure 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 4: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Disease Type (in %), 2022
Figure 5: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Diagnosis and Treatment (in %), 2022
Figure 6: Global: Anti-Tuberculosis Therapeutics Market: Breakup by End User (in %), 2022
Figure 7: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Region (in %), 2022
Figure 8: Global: Anti-Tuberculosis Therapeutics (Active TB) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Anti-Tuberculosis Therapeutics (Active TB) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Anti-Tuberculosis Therapeutics (Treatment) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Anti-Tuberculosis Therapeutics (Treatment) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Anti-Tuberculosis Therapeutics (Homecare) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Anti-Tuberculosis Therapeutics (Homecare) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: North America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: North America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: United States: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: United States: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: Canada: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: Canada: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: Asia-Pacific: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: Asia-Pacific: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: China: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: China: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: Japan: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: Japan: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: India: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: India: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: South Korea: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: South Korea: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: Australia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: Australia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: Indonesia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: Indonesia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Europe: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Europe: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: Germany: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: Germany: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: France: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: France: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: United Kingdom: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: United Kingdom: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: Italy: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: Italy: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: Spain: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: Spain: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Russia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Russia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Latin America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Latin America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Brazil: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Brazil: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Mexico: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Mexico: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 72: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 73: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Breakup by Country (in %), 2022
Figure 74: Middle East and Africa: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 75: Global: Anti-Tuberculosis Therapeutics Industry: Drivers, Restraints, and Opportunities
Figure 76: Global: Anti-Tuberculosis Therapeutics Industry: Value Chain Analysis
Figure 77: Global: Anti-Tuberculosis Therapeutics Industry: Porter's Five Forces Analysis
